Adherence-enhancing interventions for active antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis
Tim Mathes A B , Sunya-Lee Antoine A and Dawid Pieper A
+ Author Affiliations
- Author Affiliations
A Institute for Research in Operative Medicine, Faculty of Health – School of Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, Building 38, D-51109 Cologne, Germany.
B Corresponding author. Email: tim.mathes@uni-wh.de
Sexual Health 11(3) 230-239 https://doi.org/10.1071/SH14025
Submitted: 27 January 2014 Accepted: 19 March 2014 Published: 26 June 2014
Abstract
Background: In sub-Saharan Africa, an estimated 23% of HIV-infected patients are nonadherent. The objective was to evaluate the effectiveness of adherence-enhancing interventions for active antiretroviral therapy (ART) in HIV-infected patients in sub-Saharan Africa. Methods: A systematic literature search was performed with the following inclusion criteria: adult HIV patients treated with ART, an intervention to enhance patient adherence, adherence rate as an outcome, a clinical or patient outcome, a randomised controlled trial and conducted in sub-Saharan Africa. Studies were selected by two reviewers independently. Data on patient characteristics, interventions, adherence definition and measures, and results were extracted. The risk of bias was evaluated by two reviewers independently. A meta-analysis was performed where appropriate. All discrepancies were discussed until consensus. Results: Six trials fulfilled all inclusion criteria. One showed statistically significant results in favour of the intervention for adherence rate and clinical outcome. The other studies showed either no significant results for any outcome or heterogeneous results depending on the outcome type. Aside from the clinical outcomes in one study, all outcomes showed a tendency in favour of the intervention groups. In the meta-analysis short message service (SMS) interventions showed a statistically significant effect on adherence (risk difference = –0.10; 95% confidence interval (CI): –0.17 to –0.03) and modified directly observed therapy (DOT) showed a significant effect on mortality (relative risk = 0.75; 95% CI: 0.44–1.26). Conclusion: The adherence-enhancing interventions (DOT, SMS interventions, counselling plus an alarm device) increased adherence only slightly, possibly because the high baseline adherence causes a ceiling effect.
Additional keywords: AIDS, directly observed therapy, HIV, SMS, text messaging.
References
[1] United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. Global Report. Geneva: UNAIDS; 2012.[2] Vrijens B, Goetghebeur E, de Klerk E, Rode R, Mayer S, Urquhart J. Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 2005; 24 2719–31.
| Modelling the association between adherence and viral load in HIV-infected patients.Crossref | GoogleScholarGoogle Scholar | 16118813PubMed |
[3] Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 109 cells/L. Ann Intern Med 2003; 139 810–6.
| Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 109 cells/L.Crossref | GoogleScholarGoogle Scholar | 14623618PubMed |
[4] Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191 339–47.
| Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtlKrtbo%3D&md5=0e815dfc41c970f95f43357252b700c9CAS | 15633092PubMed |
[5] Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, et al Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010; 24 395–403.
| Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial.Crossref | GoogleScholarGoogle Scholar | 20099399PubMed |
[6] Reda AA, Biadgilign S. Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa. AIDS Res Treat 2012; 574656
| Determinants of adherence to antiretroviral therapy among HIV-infected patients in Africa.Crossref | GoogleScholarGoogle Scholar | 22461980PubMed |
[7] Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296 679–90.
| Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XotFagtbY%3D&md5=f47f6b140b78796609f21ec95a951843CAS | 16896111PubMed |
[8] World Health Organisation (WHO). Adherence to long-term therapies-evidence for action. Geneva: WHO; 2003.
[9] Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 2011; 11 942–51.
| Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies.Crossref | GoogleScholarGoogle Scholar | 22030332PubMed |
[10] Schwartländer B, Grubb I, Perriëns J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368 541–6.
| The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world.Crossref | GoogleScholarGoogle Scholar | 16890843PubMed |
[11] Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al Medication compliance and persistence: terminology and definitions. Value Health 2008; 11 44–7.
| Medication compliance and persistence: terminology and definitions.Crossref | GoogleScholarGoogle Scholar | 18237359PubMed |
[12] Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother 2011; 45 372–9.
| Levels of adherence required for virologic suppression among newer antiretroviral medications.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXksVGktLw%3D&md5=41e6e371c5b29da17f77590f66b0b32aCAS | 21386024PubMed |
[13] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG). Rilpivirin – Nutzenbewertung gemäß § 35a SGB V Dossierbewertung. Cologne: IQWIG; 2012.
[14] Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343 d5928
[15] Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, et al A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011; 8 e1000422
| A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.Crossref | GoogleScholarGoogle Scholar | 21390262PubMed |
[16] Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, et al Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010; 24 1273–80.
| 1:CAS:528:DC%2BC3cXmt1eht7k%3D&md5=9c9774927e8503235e8348697ce2d9a7CAS | 20453627PubMed |
[17] Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, et al Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007; 46 238–44.
| Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXhtVOkur7P&md5=7e11a53ef32072e6326e5409b0965f81CAS | 17693890PubMed |
[18] Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010; 376 1838–45.
| Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial.Crossref | GoogleScholarGoogle Scholar | 21071074PubMed |
[19] Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, et al Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 2008; 48 611–9.
| Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXptFSmurk%3D&md5=2606ac1d8a1d8669e287cf22973e320cCAS | 18645509PubMed |
[20] Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lester RT, Mills EJ, Smieja M, et al The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy. PLoS ONE 2012; 7 e46909
| The Cameroon Mobile Phone SMS (CAMPS) trial: a randomized trial of text messaging versus usual care for adherence to antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvV2js7bL&md5=c032f0195c30b44126fb675df9d8623cCAS | 23236345PubMed |
[21] Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, et al Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 2010; 54 167–79.
| 20375848PubMed |
[22] Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007; 12 687–94.
| Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya.Crossref | GoogleScholarGoogle Scholar | 17445136PubMed |
[23] Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3 e438
| Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators.Crossref | GoogleScholarGoogle Scholar | 17121449PubMed |
[24] Keogh-Brown MR, Bachmann MO, Shepstone L, Hewitt C, Howe A, Ramsay CR, et al Contamination in trials of educational interventions. Health Technol Assess 2007; 11 iii, ix–107.
[25] Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010; 340 c2073
| An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials.Crossref | GoogleScholarGoogle Scholar | 20442226PubMed |
[26] Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, Martin-Hilber A. Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Trop Med Int Health 2010; 15 16–33.
| Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography.Crossref | GoogleScholarGoogle Scholar | 20586957PubMed |
[27] Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 2010; 5 70–7.
| Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities.Crossref | GoogleScholarGoogle Scholar | 20046150PubMed |
[28] Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45 4–8.
| HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXksFOltro%3D&md5=b124c1a0929ee3be1238b3cfb7920684CAS | 17460469PubMed |
[29] Buscher A, Hartman C, Kallen MA, Giordano TP. Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naive, HIV patients. HIV Clin Trials 2011; 12 244–54.
| Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naive, HIV patients.Crossref | GoogleScholarGoogle Scholar | 22180522PubMed |
[30] Gorenoi V, Schoenermark MP, Hagen A. Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes (structured abstract). Cologne: German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information; 2007.
[31] Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; 2 CD000011
| 18425859PubMed |
[32] Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011; 25 825–34.
| Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders.Crossref | GoogleScholarGoogle Scholar | 21252632PubMed |
[33] Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev 2012; 3 CD009756
| 22419345PubMed |
[34] Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010; 3 CD004371
| 20238331PubMed |
[35] Balfour L, Tasca GA, Kowal J, Corace K, Cooper CL, Angel JB, et al Development and validation of the HIV Medication Readiness Scale. Assessment 2007; 14 408–16.
| Development and validation of the HIV Medication Readiness Scale.Crossref | GoogleScholarGoogle Scholar | 17986658PubMed |
[36] Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs 2013; 73 545–62.
| Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhvVWmurzE&md5=25ecd37a40b3c0825674f35015765e47CAS | 23588595PubMed |
